H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 48 from CHF 43 and keeps a Buy rating on the shares. The firm cites evenamide’s clinical advancement and the company’s “multiple value inflection points later this year” for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NWPHF:
- Newron bolsters finances as Evenamide enters pivotal global Phase III
- Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul
- Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress
- Newron extends EIB loan maturities to align financing with Evenamide milestones
- Newron refreshes board with CNS and capital markets experts ahead of AGM